HRP20090211T1 - Krute forme magnezijeve soli (s)-omeprazola i postupci za njihovu pripravu - Google Patents

Krute forme magnezijeve soli (s)-omeprazola i postupci za njihovu pripravu

Info

Publication number
HRP20090211T1
HRP20090211T1 HR20090211T HRP20090211T HRP20090211T1 HR P20090211 T1 HRP20090211 T1 HR P20090211T1 HR 20090211 T HR20090211 T HR 20090211T HR P20090211 T HRP20090211 T HR P20090211T HR P20090211 T1 HRP20090211 T1 HR P20090211T1
Authority
HR
Croatia
Prior art keywords
omeprazole
magnesium salt
processes
preparation
solid forms
Prior art date
Application number
HR20090211T
Other languages
English (en)
Inventor
Berenguer Maimo Ramon
Coppi Laura
Gasanz Guill�n Yolanda
Medrano Rup�rez Jorge
Original Assignee
Esteve Quimica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Quimica filed Critical Esteve Quimica
Publication of HRP20090211T1 publication Critical patent/HRP20090211T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Kruta forma magnezijeve soli S-omeprazola, naznačena time da njen difraktogram X-zraka sadržava karakteristične peak-ove jačeg intenziteta od ostalih pri približno 5.9, 6.5 i 7.6 stupnjeva 2 theta kod zračenja CuKα1 λ=1.5406 A bez ijednog drugog izraženijeg peak-a. Patent sadrži još 25 patentnih zahtjeva.
HR20090211T 2004-07-02 2009-04-08 Krute forme magnezijeve soli (s)-omeprazola i postupci za njihovu pripravu HRP20090211T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401729A ES2246149B1 (es) 2004-07-02 2004-07-02 Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
PCT/EP2005/053062 WO2006003163A1 (en) 2004-07-02 2005-06-29 Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation

Publications (1)

Publication Number Publication Date
HRP20090211T1 true HRP20090211T1 (hr) 2009-05-31

Family

ID=34972307

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090211T HRP20090211T1 (hr) 2004-07-02 2009-04-08 Krute forme magnezijeve soli (s)-omeprazola i postupci za njihovu pripravu

Country Status (19)

Country Link
US (1) US7902370B2 (hr)
EP (1) EP1765807B1 (hr)
JP (2) JP5575366B2 (hr)
KR (1) KR101290035B1 (hr)
CN (1) CN1976923B (hr)
AT (1) ATE425975T1 (hr)
AU (1) AU2005259205B2 (hr)
CA (1) CA2570559C (hr)
CY (1) CY1109048T1 (hr)
DE (1) DE602005013382D1 (hr)
DK (1) DK1765807T3 (hr)
ES (2) ES2246149B1 (hr)
HR (1) HRP20090211T1 (hr)
MX (1) MXPA06014736A (hr)
NO (1) NO20070635L (hr)
NZ (1) NZ552458A (hr)
PT (1) PT1765807E (hr)
WO (1) WO2006003163A1 (hr)
ZA (1) ZA200700865B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CN103044400A (zh) * 2012-12-21 2013-04-17 北京华禧联合科技发展有限公司 埃索美拉唑镁盐及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
AU777667B2 (en) * 1999-08-26 2004-10-28 Aaipharma Incorporated Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) * 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
EP1706397A4 (en) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd AMORPHOUS FORM OF OMEPRAZOLE SALTS
DE60123800T2 (de) * 2000-08-04 2007-10-11 Takeda Pharmaceutical Co. Ltd. Salze von benzimidazol-derivaten und deren verwendung
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
AU2003262992A1 (en) * 2002-08-30 2004-03-19 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.

Also Published As

Publication number Publication date
ES2246149B1 (es) 2007-06-01
ZA200700865B (en) 2009-09-30
MXPA06014736A (es) 2007-06-25
JP2014169302A (ja) 2014-09-18
KR101290035B1 (ko) 2013-07-30
US20070249684A1 (en) 2007-10-25
EP1765807A1 (en) 2007-03-28
US7902370B2 (en) 2011-03-08
JP5575366B2 (ja) 2014-08-20
ES2246149A1 (es) 2006-02-01
AU2005259205B2 (en) 2011-01-27
CN1976923B (zh) 2011-08-24
CY1109048T1 (hr) 2014-07-02
ES2323319T3 (es) 2009-07-13
ATE425975T1 (de) 2009-04-15
JP2008505160A (ja) 2008-02-21
NO20070635L (no) 2007-03-20
CA2570559A1 (en) 2006-01-12
KR20070031992A (ko) 2007-03-20
CN1976923A (zh) 2007-06-06
EP1765807B1 (en) 2009-03-18
AU2005259205A1 (en) 2006-01-12
WO2006003163A1 (en) 2006-01-12
PT1765807E (pt) 2009-04-13
DE602005013382D1 (de) 2009-04-30
DK1765807T3 (da) 2009-06-08
NZ552458A (en) 2010-07-30
CA2570559C (en) 2012-08-28

Similar Documents

Publication Publication Date Title
EP1804811A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF FLAVIVERS, PESTIVERS AND HEPACIVIRES
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2006102112A3 (en) Prokineticin 1 receptor
IS8418A (is) 1,4-tvíútskiptar ísókínílónafleiður sem RAF-kínasatálmar sem eru gagnlegar til að meðhöndla fjölgunarsjúkdóma
HK1198922A1 (en) Compositions for treating or preventing oxalate-related disease
EP1723227A4 (en) NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
EP1827389A4 (en) NANOTEHICOUS COMPOSITIONS WITH DELAYED RELEASE AND METHOD OF USE
MY146989A (en) Kinase inhibitors
ZA200709763B (en) 2,4-diamino-pyrimidines used as aurora inhibitors
PL1761266T3 (pl) Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
MX2009001327A (es) Compuestos de indol.
EP2177224A3 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1806619A4 (en) RESERVE COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND COMPOUND
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
ZA200801441B (en) p38MAP kinase inhibitors and methods for using the same
HK1103073A1 (en) Substituted diaza-spiro-[5.5-undecane derivatives and their use as neurokinin antagonists
NL1031626A1 (nl) Verbindingen die bruikbaar zijn in therapie.
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
TWI315449B (en) Positive resist composition, method for forming resist pattern and compound
TWI318724B (en) Method for forming positive resist composition, positive resist composition, and method for forming resist pattern
HRP20090211T1 (hr) Krute forme magnezijeve soli (s)-omeprazola i postupci za njihovu pripravu
EP1643306A4 (en) RESIN COMPOSITION, MULTILAYER BODY AND METHOD FOR FORMING A RESISTANCE STRUCTURE